Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck, Intercell End MRSA Vax-Trial | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Merck, Intercell End MRSA Vax-Trial

Merck and Intercell AG have terminated the Phase II/III trial investigating Staphylococcus aureus vaccine, V710, following analysis of the trial data and the unanimous recommendation by an independent Data Monitoring Committee (DMC).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck and Intercell AG have terminated the Phase II/III trial investigating Staphylococcus aureus vaccine, V710, following analysis of the trial data and the unanimous recommendation by an independent Data Monitoring Committee (DMC).

The DMC informed Merck that the trial had not met the formal futility criteria but recommended that enrollment in the trial be suspended pending additional analyses of the benefits and risks of vaccination. The decision to terminate was based on the observation that V710 was unlikely to demonstrate a statistically significant clinical benefit, as well as a safety concern regarding overall mortality and multi-organ dysfunction that occurred with greater frequency in vaccine recipients, compared with placebo.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters